中国P站

Ultra-rapid-acting insulins; Postprandial glucose; Meta-analysis; Randomized controlled trials; Type 1 diabetes; Type 2 diabetes; Glycemic control; Mealtime insulin; Faster aspart; Ultra-rapid lispro; Pharmacokinetics; Hypoglycemia risk; HbA1c reduction; Insulin absorption; Glucose excursion; Clinical efficacy; Insulin therapy; Diabetes management; Safety outcomes; Injection timing

Introduction

Postprandial hyperglycemia remains a critical challenge in the management of diabetes mellitus, particularly in both type 1 and type 2 diabetes. Controlling glucose levels following meals is essential not only for achieving glycemic targets but also for reducing the risk of long-term complications. Conventional rapid-acting insulins have limitations in mimicking the physiological first-phase insulin response, often resulting in suboptimal postprandial glucose control [1-5]. In response to this limitation, ultra-rapid-acting insulins (URAI), including faster aspart and ultra-rapid lispro, have been developed to offer faster onset and absorption. These insulins aim to better match endogenous insulin secretion, improving glycemic control. A growing number of randomized controlled trials (RCTs) have examined their efficacy and safety compared to traditional rapid-acting analogs. This meta-analysis seeks to synthesize findings across these trials, evaluating the clinical benefit of URAIs in postprandial glucose management [6-10].

Discussion

Ultra-rapid-acting insulins are engineered to be absorbed more quickly into the bloodstream, allowing them to act faster than traditional insulins. The meta-analysis includes data from multiple RCTs comparing ultra-rapid analogs with established rapid-acting insulins like insulin aspart and insulin lispro. In pooled analyses, ultra-rapid formulations administered at mealtime showed superior control of 1-hour and 2-hour postprandial glucose excursions in type 1 and type 2 diabetes populations. These reductions ranged between 10–20 mg/dL on average, highlighting their improved pharmacodynamic profile.

Notably, HbA1c improvements with ultra-rapid insulins were modest. While postprandial glucose levels were better controlled, overall HbA1c reduction did not differ significantly from conventional insulin analogs. However, reduced glycemic variability and lower peak glucose spikes may contribute to improved quality of life and reduced complication risk over time.

The timing of administration played a significant role in outcomes. URAIs were most effective when given just before or immediately with meals. Postmeal administration showed diminished benefits, indicating that the faster onset is only advantageous if timed appropriately.

From a safety perspective, the incidence of severe hypoglycemia was comparable between ultra-rapid and conventional insulins. However, there was a slightly increased incidence of early postprandial hypoglycemia, especially in individuals with type 1 diabetes using ultra-rapid lispro. Most trials reported mild injection site reactions more frequently in URAI groups, though these were not considered clinically significant.

Patient-reported outcomes such as treatment satisfaction and injection burden were also considered. Some participants preferred URAIs due to greater flexibility in timing and better perceived control after meals. Nonetheless, factors such as cost, access, and individual insulin sensitivity still influence clinical decision-making.

Conclusion

Ultra-rapid-acting insulins represent an important advancement in mealtime insulin therapy, demonstrating superior postprandial glucose control compared to traditional rapid-acting analogs. Their rapid onset enables better alignment with physiological insulin secretion, which may help in reducing glucose spikes and long-term glycemic variability. While improvements in HbA1c are modest, the overall benefits for daily glycemic management are notable, particularly for patients struggling with post-meal hyperglycemia. Safety profiles are similar to existing options, though care should be taken with dosing timing to minimize early hypoglycemia risk. Ultra-rapid-acting insulins offer a valuable tool in the evolving landscape of diabetes management, particularly when individualized to patient needs and lifestyles.

References

1. Sackett DL, Haynes BR, Tugwell P, Guyatt GH (1991) . London: Lippincott, Williams and Wilkins.

2. Mullan F (1984) . Public Health Rep 99: 442–445.

   ,

3. Mullan F, Nutting PA (1986) . Fam Med 18: 221–225.

   ,

4. Abramson JH (1984) . Public Health Rep 99: 437–441.

   ,

5. Hart JT (1974) . J R Coll Physicians Lond 8: 299–314.

   ,

6. Pickles WN (1939) . Bristol: John Wright and Sons.

7. Fry J (1979) . Lancaster: MT Press.

8. Hodgkin K (1985) . Churchill Livingstone.

9. Last RJ (2001) . Oxford: International Epidemiological Association.

10. Kroenke K (1997) . J Gen Intern Med 12: 509–510.